ArticleKorean circulation journal2026
Current Therapeutic Patterns of Pulmonary Arterial Hypertension in Korea: A Five-Year Follow-up of the PHOENIKS Longitudinal Cohort.
Article in Korean circulation journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cause-specific outcomes in systemic sclerosis-associated, systemic lupus erythematosus-associated, and idiopathic pulmonary hypertension with significant pre-capillary components: a competing risk analysis.Clinical rheumatology · 2026Article
- Insights From the PHOENIKS Cohort: Shaping the Future of Pulmonary Arterial Hypertension (PAH) Management in Korea.Korean circulation journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
BACKGROUND AND
objectivesThe 2022 revised pulmonary hypertension guidelines emphasize risk stratification to enhance outcomes, necessitating investigation into adherence. This study aimed to examine the treatment patterns of patients in the Pulmonary Arterial Hypertension (PAH) Platform for deep Phenotyping in Korean Subjects (PHOENIKS) study cohort.
methodsA total of 321 patients from the PHOENIKS cohort were included, consisting of 101 patients in phase 1 (2018-2020) and 220 in phase 2 (2021-2023). A total of 275 patients with either idiopathic PAH or associated PAH were included in the final analysis. Risk assessment was conducted utilizing an online calculator that integrates multiple validated risk stratification models. Adherence to the revised guidelines was evaluated, and survival outcomes were analyzed over the study period.
resultsThe cohort consisted primarily of middle-aged and female patients (mean age 51.96±15 years, 71% female). A total of 53% had idiopathic PAH and 47% had associated PAH. Intermediate-risk patients comprised 62% of the cohort during the initial diagnosis. The proportion of low-risk patients increased from 34% to 64% throughout the follow-up period. Adherence to the revised guidelines slightly improved during the study period, though only 26% of patients demonstrated compliance. The one-year survival rate was 96%, whereas the 3-year survival rate was 87%.
conclusionsThe current Korean PAH treatment strategy must be improved to align with the revised guidelines and optimize patient outcomes. Further efforts are needed to change health insurance coverage criteria to enhance guideline adherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.